icon
icon
icon
icon
Upgrade
icon

Lilly (LLY.US) CEO: Alzheimer's drug can have 'preventative' effect

AInvestSunday, Oct 13, 2024 11:10 pm ET
1min read

Zhitong Finance learned that media reports on Sunday said that David Ricks, CEO of Eli Lilly (LLY.US), told then-UK Health Secretary Victoria Atkins in December last year that the company's new Alzheimer's disease candidate drug may be a one-time treatment, although the data supporting this claim is limited. Ricks reportedly said that donanemab, which reduces amyloid plaques in the brain believed to cause Alzheimer's disease, "could treat those diagnosed with Alzheimer's disease before symptoms appear." The report quoted Atkins as emphasizing the "game-changing potential" of the candidate drug.

However, Eli Lilly has not yet proven the drug's potential. The report also said that the study plan to assess donanemab's potential preventive benefits will not be completed until the end of 2027, and this was not clearly stated in the meeting records disclosed under the Freedom of Information Act.

Eli Lilly said in an interview that "the possibility of treating Alzheimer's disease before symptoms appear, and we are verifying this through ongoing trials." Donanemab is under review by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of early symptomatic Alzheimer's disease. Donanemab is marketed under the Kisunla brand and has been approved this year in the US and Japan. Its competitors are Biogen's (BIIB.US) Leqembi (lecanemab) and Eisai.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.